ArticleInternational journal of molecular sciences2015
Factor XIII B subunit polymorphisms and the risk of coronary artery disease.
Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.Molecular and cellular biochemistry · 2018Trial
- Fibrin formation and lysis in hyperglycaemia - molecular and cellular drivers.Current opinion in hematology · 2026Review
- Protective Effect of Factor XIII Intron-K G Allele on Subclinical Vascular Disease.International journal of molecular sciences · 2025Article
- Identifcation of candidate biomarkers for polyarteritis nodosa using data-independent acquisition mass spectrometry.American journal of translational research · 2025Article
- Review
- Alu retrotransposons and COVID-19 susceptibility and morbidity.Human genomics · 2021Review
- The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations.Journal of thrombosis and haemostasis : JTH · 2020Article
- Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis.Advances in therapy · 2019Article
- Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients.Scientific reports · 2018Observational
- Plasma protein profiling in patients undergoing coronary artery bypass grafting surgery and clinical significance.Oncotarget · 2017Article
- Newly-Recognized Roles of Factor XIII in Thrombosis.Seminars in thrombosis and hemostasis · 2016Review
- Correction: Mezei, Z.A., et al; Factor XIII B subunit polymorphisms and the risk of coronary artery disease. Int. J. Mol. Sci. 2015, 16, 1143-1159.International journal of molecular sciences · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the case-control study was to explore the effect of coagulation factor XIII (FXIII) B subunit (FXIII-B) polymorphisms on the risk of coronary artery disease, and on FXIII levels. In the study, 687 patients admitted for coronary angiography to investigate suspected coronary artery disease and 994 individuals representing the Hungarian population were enrolled. The patients were classified according to the presence of significant coronary atherosclerosis (CAS) and history of myocardial infarction (MI). The F13B gene was genotyped for p.His95Arg and for intron K nt29756 C>G polymorphisms; the latter results in the replacement of 10 C-terminal amino acids by 25 novel amino acids. The p.His95Arg polymorphism did not influence the risk of CAS or MI. The FXIII-B intron K nt29756 G allele provided significant protection against CAS and MI in patients with a fibrinogen level in the upper tertile. However, this effect prevailed only in the presence of the FXIII-A Leu34 allele, and a synergism between the two polymorphisms was revealed. Carriers of the intron K nt29756 G allele had significantly lower FXIII levels, and FXIII levels in the lower tertile provided significant protection against MI. It is suggested that the protective effect of the combined polymorphisms is related to decreased FXIII levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.